Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2018, 2018, roč. 13, č. 3, s. 222-223.